Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-03-26

Clinical Trial Update: An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing vandetanib (ZD6474) to placebo in medullary thyroid carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Vandetanib (vandetanib)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Thyroid Cancer | Phase 3 | Status: COMPLETED | Results posted: 2012-03-26